Last reviewed · How we verify
NCT05028660: AUR93A
AURORAX-0093A: Glycosaminoglycan Profiling for Prognostication of Muscle-invasive Bladder Cancer - a Pilot Study
trial testing GAG score in Muscle-Invasive Bladder Carcinoma in 43 participants. Completed in 30 April 2025.
30 April 2025
Quick facts
| Lead sponsor | Elypta |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 43 |
| Start date | 21 July 2021 |
| Primary completion | 30 April 2025 |
| Estimated completion | 30 April 2025 |
| Sites | 5 locations across Denmark, Italy, Sweden |
Drugs / interventions tested
- GAG score
Conditions studied
- Muscle-Invasive Bladder Carcinoma — all drugs for Muscle-Invasive Bladder Carcinoma →
Sponsor
Elypta
Who can join
18 and older, any sex, with Muscle-Invasive Bladder Carcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
AURORAX-0093A (AUR93A) is a pilot cohort observational study that will explore the use of urine and plasma glycosaminoglycans (GAGs) to prognosticate muscle-invasive bladder cancer (MIBC) patients elected for neo-adjuvant chemotherapy (NAC).
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Advances in Liquid Biopsy for Diagnosis of Bladder Cancer.
Seok J, Kwak Y, Kim S, Kim EM, et al · · 2024 · cited 6× · PMID 38956768 · DOI 10.5213/inj.2448198.099
Verify or expand the search:
- PubMed search for NCT05028660
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of GAG score
Trials testing the same drug.
- NCT04006405 — AURORAX-0087A: GAG Scores for Surveillance of Recurrence in Leibovich Points ≥5 Non-metastatic ccRCC · completed
Other recruiting trials for Muscle-Invasive Bladder Carcinoma
Currently open trials in the same condition.
- NCT07339761 — Supporting Sexual Health in Bladder Cancer Patients: A Sequential Mixed-Methods Intervention Study · NA · recruiting
- NCT07234968 — Clinical Trial to Evaluate Post-Operative Outcomes of Ureteral Stent vs Ureteral Stent Free Radical Cystectomy · NA · recruiting
- NCT06537154 — NEO-BLAST: Neoadjuvant Therapy for Bladder Cancer Followed by Active Surveillance vs Treatment · Phase 2, PHASE3 · recruiting
- NCT06470282 — Enfortumab Vedotin and Pembrolizumab Combined With Radiotherapy in Muscle Invasive Bladder Cancer · Phase 1, PHASE2 · recruiting
- NCT06529822 — Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease · Phase 1 · recruiting
Other Elypta trials
Trials by the same sponsor.
- NCT04006405 — AURORAX-0087A: GAG Scores for Surveillance of Recurrence in Leibovich Points ≥5 Non-metastatic ccRCC · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05028660 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Elypta
- Last refreshed: 9 May 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05028660.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing